Benzinga | Dec 14, 2020 05:13AM EST

SVB Leerink Maintains Outperform on Amicus Therapeutics, Raises Price Target to $30

SVB Leerink analyst Joseph Schwartz maintains Amicus Therapeutics (NASDAQ:FOLD) with a Outperform and raises the price target from $24 to $30.